AngioDynamics (NASDAQ:ANGO) Issues Earnings Results, Beats Estimates By $0.07 EPS

AngioDynamics (NASDAQ:ANGO) posted its earnings results on Thursday. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07, FiscalAI reports. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $14.19 on Thursday. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29. The firm has a market capitalization of $596.69 million, a price-to-earnings ratio of -16.31 and a beta of 0.30. The business’s 50 day moving average price is $15.46 and its 200-day moving average price is $13.11.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Quarterly results exceeded expectations: AngioDynamics reported revenue of $80.9 million, above the $80.5 million consensus estimate, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, and the GAAP net loss narrowed to $7.1 million from $10.9 million. AngioDynamics Fiscal 2027 First-Quarter Financial Results
• Positive Sentiment: Medical technology growth was strong: Med Tech sales rose 13.2% to $39.9 million, led by Auryon sales growth of 14.7% and NanoKnife sales growth of 29.0%. Gross margin also expanded 410 basis points to 59.4%, indicating improved operating performance.
• Positive Sentiment: Pipeline and leadership developments may support the outlook: The FDA approved an IDE for a NanoKnife feasibility study in benign prostatic hyperplasia, while Eric Honroth is set to become president and CEO on November 2, 2026. CEO Appointment
• Neutral Sentiment: Full-year guidance was reiterated: Fiscal 2027 revenue is expected at $336 million to $341 million, slightly above the $337.6 million analyst consensus at the midpoint. EPS guidance of $(0.29) to $(0.24) is broadly in line with the $(0.26) consensus estimate.
• Negative Sentiment: Profitability and liquidity remain risks: The company still reported a GAAP loss, negative net margin and negative return on equity. It used $15.3 million in operating cash during the quarter, leaving $34.0 million in cash at August 31.
• Negative Sentiment: Insider selling may temper sentiment: A senior vice president sold 23,370 shares for approximately $344,000, with no reported insider purchases during the past six months.

Insider Activity

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on ANGO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Canaccord Genuity Group lifted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright boosted their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.